ADC Therapeutics SA (ADCT)

NYSE: ADCT · USD

$1.61

+0.02 (+1.3%)· Recorded snapshot

Market cap	205.5M
Revenue (ttm)	79.6M
Net income (ttm)	-96.9M
EPS (ttm)	-$0.65
Shares out	127.7M
Volume	500,799
Beta	1.86

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 79.6M
Net income (ttm): -96.9M
EPS (ttm): -$0.65
Market cap: 205.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-25.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ADCT indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001771910
Company name	ADC Therapeutics SA
Country	Switzerland
Country code	US
CUSIP number	H0036K147
Earnings date	2026-11-09
Earnings time	bmo
Employees	193
Employees change	-72
Employees growth	-27.17%
Enterprise value	$424.6M
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2011
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2020-05-15
Is primary listing	Yes
Is SPAC	No
ISIN number	CH0499880968
Last 10-K release date	2026-03-10
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$205.5M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$1.61
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ADCT
Website	https://www.adctherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-40.37%
EV/Sales	5.25x
FCF / EV yield	-24.5%
FCF yield	-51.53%
Forward EV/Sales	4.95x
Forward P/S	2.35x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/S ratio	2.49x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-118.19%
EBITDA margin	-117.75%
Gross margin	-11.59%
Operating margin	-118.19%
Pretax margin	-122.28%
Profit margin	-121.77%
Profit per employee	$-502,114
Revenue per employee	$412,352
ROA	-19.57%
ROA (5Y)	-22.35%
ROCE	-48.72%
ROIC	-25.47%
SBC / revenue	12.14%
Tax / revenue	-0.51%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	2
Net income growth quarters	4
Net income growth years	2
Revenue growth	3.03%
Revenue growth (Q)	2.17%
Revenue growth (QoQ)	-7.69%
Revenue growth 3Y	-24.43%
Revenue growth 5Y	84.13%
Revenue growth quarters	1
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-32,000
Depreciation and amortization	$353,500
EBIT	$-94.1M
EBITDA	$-93.7M
EPS	$-0.65
FCF per share	$-0.80
Financing cash flow	$56.2M
Free cash flow	$-102.3M
Free cash flow minus SBC	$-112M
Gross profit	$-9.2M
Income taxes	$-404,000
Investing cash flow	$627,000
Net cash flow	$-45.5M
Net income	$-96.9M
Operating cash flow minus SBC	$-111.9M
Operating income	$-94.1M
Revenue	$79.6M
Stock-based compensation	$9.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-8.02
Book value per share	$-1.79
Interest coverage	-1.8
Long-term assets	$17.7M
Long-term liabilities	$421.3M
Net cash (debt)	$-219.1M
Net cash / market cap	-110.36%
Piotroski F-Score	3
Property, plant and equipment	$1.1M
Shareholders' equity	$-228.2M
Tangible book value	$-228.2M
Tangible book value per share	$-1.79
Total assets	$279.4M
Total cash	$219.1M
Total debt	$438.2M
Total liabilities	$507.6M
WACC	11%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.26
Current assets	$261.7M
Current liabilities	$86.3M
Current ratio	3.03
Inventory turnover	7.83
Net working capital	$-16.5M
Quick ratio	2.86
Working capital	$175.4M
Working capital turnover	0.37

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-38.27%
Dividend yield	0%
Shareholder yield	-38.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.00
1D price change	1.26%
1M price change	26.77%
1M total return	26.77%
1W price change	7.33%
1W total return	7.33%
1Y price change	-62.47%
1Y return CAGR	-62.5%
1Y total return	-62.47%
20-day SMA	$1.48
200-day SMA	$2.50
3M price change	41.23%
3M total return	41.23%
3Y price change	130%
3Y return CAGR	31.99%
3Y total return	130%
50-day SMA	$1.29
50-day SMA vs 200-day SMA	50under200
52-week high	$4.98
52-week high date	2026-03-11
52-week low	$0.78
52-week low date	2026-06-08
5Y price change	-94.25%
5Y return CAGR	-43.52%
5Y total return	-94.25%
6M price change	-57.18%
6M total return	-57.18%
All-time high	$56.59
All-time high date	2020-07-02
All-time low	$0.36
All-time low date	2023-11-13
Average true range (ATR)	$0.14
Average volume	1.6M
Beta (1Y)	3.52
Beta (2Y)	2.57
Beta (5Y)	1.86
Change from 52-week high	-67.67%
Change from 52-week low	106.52%
Change from all-time high	-97.15%
Change from all-time low	347.35%
Change from open	1.9%
Day's gap	-0.63%
Dollar volume	$806,286
High price	$1.63
Low price	$1.55
Monthly RSI	39.04
Open price	$1.58
Position in 52-week range	75%
Premarket change	1.26%
Premarket close	$1.59
Premarket price	$1.61
Previous close	$1.59
Price vs 150-day SMA	-19.58%
Price vs 20-day SMA	8.93%
Price vs 200-day SMA	-35.65%
Price vs 50-day SMA	25.29%
Relative volume	0.31
Return from IPO open	-94.82%
Return from IPO price	-91.82%
RSI	58.19
Sharpe ratio	-0.44
Sharpe ratio (3Y)	0.77
Sharpe ratio (5Y)	-0.07
Sortino ratio	-0.49
Sortino ratio (3Y)	1.3
Sortino ratio (5Y)	-0.04
Volume	500.8K
Weekly RSI	46.39
YTD price change	-54.39%
YTD total return	-54.39%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	88.6M
Float percentage	69.37%
Shares change (QoQ)	21.9%
Shares change (YoY)	38.27%
Shares held by insiders	3.84%
Shares held by institutions	33.32%
Shares outstanding	127.7M
Short % of float	7.79%
Short % of shares	5.4%
Short ratio	4.7 days

Deeper analysis on ADCT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ADCT report

Is a complete ADCT research report available?

No complete published report is available for ADC Therapeutics SA (ADCT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ADC Therapeutics SA (ADCT)

Price

Financial snapshot

Fair-value bridge

Latest news · ADCT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ADCT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ADCT

Frequently asked questions